Financial reports
10-Q
2016 Q3
Quarterly report
8 Nov 16
10-Q
2016 Q2
Quarterly report
8 Aug 16
10-Q
2016 Q1
Quarterly report
10 May 16
10-K/A
2015 FY
Annual report (amended)
29 Apr 16
10-K
2015 FY
Annual report
29 Feb 16
10-Q
2015 Q3
Quarterly report
6 Nov 15
10-Q
2015 Q2
Quarterly report
7 Aug 15
ARS
2014 FY
Annual report to shareholders
30 Jun 15
10-Q
2015 Q1
Quarterly report
8 May 15
Current reports
8-K
Entry into a Material Definitive Agreement
16 Feb 17
8-K
ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
6 Feb 17
8-K
Entry into a Material Definitive Agreement
10 Jan 17
8-K
Other Events
8 Dec 16
8-K
Departure of Directors or Certain Officers
7 Dec 16
8-K
Other Events
30 Nov 16
8-K
ARIAD Announces Data Presentations at the World Conference on Lung Cancer
18 Nov 16
8-K
ARIAD Reports Third Quarter 2016 Financial Results
7 Nov 16
8-K
ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib
31 Oct 16
8-K
ARIAD Announces Regulatory Approval for Iclusig® (ponatinib) in Japan
29 Sep 16
Registration and prospectus
15-12B
Securities registration termination
27 Feb 17
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Feb 17
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Feb 17
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Feb 17
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Feb 17
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Feb 17
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Feb 17
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Feb 17
25-NSE
Exchange delisting
16 Feb 17
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Feb 17
Proxies
DEFA14A
Additional proxy soliciting materials
8 Jun 16
DEF 14A
Definitive proxy
8 Jun 16
PRE 14A
Preliminary proxy
27 May 16
DEF 14A
Definitive proxy
25 Jun 15
DEFA14A
Additional proxy soliciting materials
29 Apr 15
DEFA14A
Additional proxy soliciting materials
26 Feb 15
DEFA14A
Additional proxy soliciting materials
19 Jun 14
DEFA14A
Additional proxy soliciting materials
19 Jun 14
DEF 14A
Definitive proxy
9 May 14
DEFA14A
Additional proxy soliciting materials
9 May 14
Other
CT ORDER
Confidential treatment order
27 Feb 17
UPLOAD
Letter from SEC
22 Dec 16
CORRESP
Correspondence with SEC
7 Dec 16
UPLOAD
Letter from SEC
23 Nov 16
NO ACT
No action letter
1 Jun 16
CT ORDER
Confidential treatment order
22 Dec 15
CT ORDER
Confidential treatment order
11 Aug 15
CT ORDER
Confidential treatment order
28 Jul 15
CT ORDER
Confidential treatment order
14 Jul 15
UPLOAD
Letter from SEC
26 Nov 14
Ownership
4
Theseus Pharmaceuticals, Inc.
15 Oct 21
3
Theseus Pharmaceuticals, Inc.
15 Oct 21
SC 13G/A
Ariad Pharmaceuticals Inc
7 Apr 17
SC 13D/A
Ariad Pharmaceuticals Inc
21 Feb 17
4
Jennifer Lyn Herron
16 Feb 17
4
Paris Panayiotopoulos
16 Feb 17
4
Jules Haimovitz
16 Feb 17
4
George Bickerstaff
16 Feb 17
4
Jayne M. Gansler
16 Feb 17
4
Manmeet Singh Soni
16 Feb 17